Multimodal records from Tempus’s de-identified oncology dataset
Price
$1,375,000
Date
2026-10-14
Buyer
Bristol Myers Squibb
Seller
Tempus AI
Type
Region
United States/Global
Market Context
BMS may use the licensed oncology records with Pathos AI’s Foundry drug-development platform. It may terminate with 12 months’ notice, but must pay a substantial termination fee whose amount remains undisclosed.
Calculated valuation signal: Approximately $27.5 million per year over a nominal five-year period. This is an estimate because the exact commencement period and quarterly payment allocation were not disclosed.
Term
Annual
(5 years)
Confidence:
High
Citation:
DatFlash (2026).
"Multimodal records from Tempus’s de-identified oncology dataset"
https://www.datflash.com/transaction/bristol-myers-squibb-tempus-ai
https://www.datflash.com/transaction/bristol-myers-squibb-tempus-ai